Research from L. Ma and colleagues has provided new data on magnetic resonance
2009 AUG 3 - (NewsRx.com) -- According to a study from Beijing, People's Republic of China, "We investigated whether baseline vessel status evaluated by magnetic resonance angiography (MRA) can be the foremost factor to classify acute ischemic stroke patients into subgroups for thrombolytic therapy within 3-6 hours of symptom onset. Acute ischemic stroke patients beyond 3 hours after symptom onset were examined by stroke magnetic resonance imaging (MRI) (diffusion- and perfusion-weighted imaging, and MRA) before and after thrombolysis treatment within 24-48 hours." "Stroke MRI was used to classify acute ischemic stroke patients into subgroups and select optimal patients for thrombolytic treatment. Clinical scores were compared to determine whether there were significant differences among subgroups. The difference in day 90 modified Rankin scale (mRS) between treated salvageable and untreated salvageable patients with recombinant tissue plasminogen activator (rt-PA) was remarkably statistically significant (p = 0.02). Treated salvageable patients had more favorable clinical outcomes as compared with the untreated salvageable patients. who did not have baseline artery occlusion were associated with more favorable clinical outcomes than untreated salvageable patients (p < 0.001). The difference between treated salvageable and patients without artery occlusion in 90 day mRS score was not statistically significant (p = 0.058). Baseline vessel status evaluated by MRA may be used as the first factor ahead of mismatch to categorize acute ischemic stroke patients into subgroups. who do not have initial vessel occlusion may not need thrombolytic therapy," wrote L. Ma and colleagues. The researchers concluded: "[Neurol Res 2009; 31:355-361]'." Ma and colleagues published the results of their research in Neurological Research (Can baseline magnetic resonance angiography (MRA) status become a foremost factor in selecting optimal acute stroke patients for recombinant tissue plasminogen activator (Rt-PA) thrombolysis beyond 3 hours' Neurological Research, 2009;31(4):355-361). For additional information, contact P.Y. Gao, Capital Med University, Beijing Tiantan Hospital, Dept. of Neuroradiology, Beijing Neurosurgery Institute, 6 Tiantan Xili, Beijing 100050, People's Republic of China. The publisher of the journal Neurological Research can be contacted at: Maney Publishing, Ste. 1C, Josephs Well, Hanover Walk, Leeds LS3 1AB, W Yorks, England. Keywords: People's Republic of China, Beijing, Angiography, Angiology, Cardiology, Enzyme Research, Hematology, Magnetic Resonance, Perfusion, Plasminogen, Therapy, Thrombolysis, Thrombolytic, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
